S&P Futures
4,704.00 +2.50 (+0.05%) Dow Futures
35,830.00 +19.00 (+0.05%) Nasdaq Futures
16,494.75 +13.50 (+0.08%) Russell 2000 Futures
2,365.40 +1.20 (+0.05%) Gold
1,861.20 -0.20 (-0.01%) Silver
24.88 -0.02 (-0.08%)
Tonix Pharmaceuticals Holding Corp. (TNXP)
Chart Events
Performance Outlook
| Previous Close | 0.5278 |
| Open | 0.5335 |
| Bid | 0.5020 x 800 |
| Ask | 0.5026 x 800 |
| Day's Range | 0.5007 - 0.5343 |
| 52 Week Range | 0.4600 - 2.1200 |
| Volume | |
| Avg. Volume | 14,994,901 |
| Market Cap | 167.022M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3960 |
| Earnings Date | Nov 08, 2021 - Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.75 |
- Motley Fool
Why Tonix Pharmaceuticals Is Up by 6% Today
Tonix Pharmaceuticals (NASDAQ: TNXP), a rather up-and-down meme stock in the biotech sector, was having a fine day on the market Tuesday. Tuesday morning, Tonix was all too happy to announce that the Food and Drug Administration (FDA) has cleared the Investigational New Drug application for its TNX-1900. The treatment of migraines has been a thorny challenge for biotechs and pharmaceutical companies for many years.
- GlobeNewswire
Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs
Approximately Four Million in U.S. Suffer from Chronic Migraine Development of TNX-1900 Also Planned for Treatment of Episodic Migraine, Craniofacial Pain and Insulin Resistance CHATHAM, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) Application to support the initiation of a Phas
- GlobeNewswire
Tonix Pharmaceuticals Announces Publication of Paper on Antiviral SARS-CoV-2 Inhibitor, TNX-3500, in JCI Insight
Early Studies in vitro Show that TNX-3500 is a Potent Antiviral Against Multiple Variants of SARS-CoV-2, the Cause of COVID-19, and Potentiates RemdesivirCHATHAM, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the publication of “Sangivamycin is highly effective against SARS-CoV-2 in vitro and has favorable drug properties,” in JCI Insight. The paper includes in vitro s
